These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33077351)

  • 1. Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors.
    Machidori A; Shiota M; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Eto M
    Urol Oncol; 2021 Jun; 39(6):365.e1-365.e7. PubMed ID: 33077351
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Morris MJ; Castellano D; Herrmann K; de Bono JS; Shore ND; Chi KN; Crosby M; Piulats JM; Fléchon A; Wei XX; Mahammedi H; Roubaud G; Študentová H; Nagarajah J; Mellado B; Montesa-Pino Á; Kpamegan E; Ghebremariam S; Kreisl TN; Wilke C; Lehnhoff K; Sartor O; Fizazi K;
    Lancet; 2024 Sep; 404(10459):1227-1239. PubMed ID: 39293462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients.
    Kobayashi H; Shiota M; Sato N; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
    Anticancer Drugs; 2022 Jan; 33(1):e541-e547. PubMed ID: 34387597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
    Haas NB; LaRiviere MJ; Buckingham TH; Cherkas Y; Calara-Nielsen K; Foulk B; Patel J; Gross S; Smirnov D; Vaughn DJ; Amaravadi R; Wellen KE; Savitch SL; Majmundar KJ; Black TA; Yee SS; He M; Min EJ; Long Q; Jones JO; Pal SK; Carpenter EL
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):448-456. PubMed ID: 33009489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer.
    Caram MEV; Kumbier K; Tsao PA; Burns J; Sparks JB; Stensland KD; Reichert ZR; Alumkal JJ; Hollenbeck BK; Shahinian V; Tsodikov A; Skolarus TA
    Cancer Med; 2024 Jun; 13(12):e7334. PubMed ID: 39143030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of prior local therapy in castration-resistant prostate cancer.
    Koura M; Shiota M; Ueda S; Matsumoto T; Kobayashi S; Monji K; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
    Jpn J Clin Oncol; 2021 Jul; 51(7):1142-1148. PubMed ID: 33621330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
    Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
    Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    De Laere B; Oeyen S; Mayrhofer M; Whitington T; van Dam PJ; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert EG; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff IE; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden GG; Rutten A; Del Favero J; Rantalainen M; Rajan P; Sleijfer S; Ullén A; Yachnin J; Grönberg H; Van Laere SJ; Lindberg J; Dirix LY
    Clin Cancer Res; 2019 Mar; 25(6):1766-1773. PubMed ID: 30209161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.
    Del Re M; Conteduca V; Crucitta S; Gurioli G; Casadei C; Restante G; Schepisi G; Lolli C; Cucchiara F; Danesi R; De Giorgi U
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):524-531. PubMed ID: 33500577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
    Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S
    Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
    Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
    Szarvas T; Csizmarik A; Váradi M; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Tschirdewahn S; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
    Urol Oncol; 2021 May; 39(5):296.e11-296.e19. PubMed ID: 33046366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
    de Wit R; Wülfing C; Castellano D; Kramer G; Eymard JC; Sternberg CN; Fizazi K; Tombal B; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Bono J
    ESMO Open; 2021 Oct; 6(5):100241. PubMed ID: 34450475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis.
    Farinea G; Calabrese M; Carfì F; Saporita I; Poletto S; Delcuratolo MD; Turco F; Audisio M; Di Stefano FR; Tucci M; Buttigliero C
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
    Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
    J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with
    Wibmer AG; Morris MJ; Gonen M; Zheng J; Hricak H; Larson S; Scher HI; Vargas HA
    J Nucl Med; 2021 Aug; 62(8):1050-1056. PubMed ID: 33419944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.
    Annala M; Taavitsainen S; Khalaf DJ; Vandekerkhove G; Beja K; Sipola J; Warner EW; Herberts C; Wong A; Fu S; Finch DL; Oja CD; Vergidis J; Zulfiqar M; Eigl BJ; Kollmansberger CK; Nykter M; Gleave ME; Chi KN; Wyatt AW
    Clin Cancer Res; 2021 Aug; 27(16):4610-4623. PubMed ID: 34083234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.